Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHEB | Q15382 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.32 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11283671 | 0.81 | CYP3A4 (0.43) | RHEBFABP3ALDH1A1HPGDCYP2A6 | |
| SCHEMBL5541601 | 0.79 | HPGD (0.48) | RHEBALDH1A1HPGDSLC6A2SLC6A3 | |
| SCHEMBL7634253 | 0.78 | CA1 (0.38) | ALDH1A1HPGDMAPK1 | |
| SCHEMBL319832 | 0.77 | CYP3A4 (0.45) | RHEBFABP3ALDH1A1HPGDSLC6A2 | |
| SCHEMBL1340460 | 0.77 | MAPT (0.46) | RHEBFABP3ALDH1A1HPGDCYP3A4 | |
| SCHEMBL30290439 | 0.77 | L3MBTL1 (0.50) | ALDH1A1HPGDARSLC6A2SLC6A3 | |
| SCHEMBL10829853 | 0.76 | TTR (0.55) | RHEBALDH1A1HPGDMRGPRX4SLC6A2 | |
| SCHEMBL304918 | 0.74 | CYP1A2 (0.48) | RHEBFABP3ALDH1A1CYP3A4 | |
| SCHEMBL5544824 | 0.72 | HTR2A (0.54) | ARSLC6A2SLC6A3SLC6A4CYP3A4 | |
| SCHEMBL5548072 | 0.71 | MEN1 (0.35) | ALDH1A1HPGDSLC6A4CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | RHEB 1317/4885FABP3 349/4885ALDH1A1 355/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.